Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia

American Journal of Cardiology

Volumn 90, Issue 10, 2002, Pages 1092-1097

  Dujovne, Carlos A ^a   Ettinger, Mark P ^a,b,c,d   McNeer, J Frederick ^a,b,c,d   Lipka, Leslie J ^a,b,c,d   LeBeaut, Alexandre P ^a,b,c,d   Suresh, Ramachandran ^a,b,c,d   Yang, B O ^a,b,c,d   Veltri, Enrico P ^a,b,c,d  

^a Kansas Foundation for Clinical Pharmacology   (United States)

^b RADIANT RESEARCH   (United States)

^c Warren Clinic   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; CHOLESTEROL; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; AZETIDINES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, HDL; LIPOPROTEINS, HDL3; MALE; MIDDLE AGED; TREATMENT OUTCOME; TRIGLYCERIDES; UNITED STATES;

EID: 0037111924     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02798-4     Document Type: Article

References (22)

1. Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults . Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA. 269:1993;3015-3023.
2. New York Heart Association . Diseases of the Heart and Blood Vessels. Nomenclature and Criteria for Diagnosis. 6th Ed. 1964;114 Little, Brown, Boston.
3. Friedewald W.T., Levy R.I., Frederickson D.S. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
4. Harris W.S., Held S.J., Dujovne C.A. Comparison of two scoring systems used to monitor diets in outpatient clinical trials. J Cardiovasc Risk. 2:1995;359-365.
5. van Heek M., France C.F., Compton D.S., McLeod R.L., Yumibe N.P., Alton K.B., Sybertz E.J., Davis H.R. Jr. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther. 283:1997;157-163.
6. van Heek M., Farley C., Compton D.S., Hoos L., Alton K.B., Sybertz E.J., Davis H.R. Jr. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol. 129:2000;1748-1754.
7. Davis H.R., Compton D.S., Hoos L., Tetzloff G., Caplen M.A., Burnett D.A. Ezetimibe (SCH58235) localizes to the brush border of small intestinal enterocyte and inhibits enterocyte cholesterol uptake and absorption. (abstr) Eur Heart J. 21:(suppl):2000;636.
8. Knopp R.H., Bays H., Manion C.V., Lipka L.J., Melani L., LeBeaut A.P., Suresh R., Veltri E.P., Ezetimibe Study Group . Effect of ezetimibe on serum concentrations of lipid-soluble vitamins. (abstr) Atherosclerosis. 2:(suppl):2001;90.
9. van Heek M., Farley C., Compton D., Hoos L., Davis H. The novel cholesterol absorption inhibitor, ezetimibe, selectively inhibits the intestinal absorption of free cholesterol in the presence and absence of exocrine pancreatic function. (abstr) Atherosclerosis. 151:2000;155.
10. van Heek M., Farley C., Compton D., Hoos L., Alton K., Sybertz E., Davis H. The potent cholesterol absorption inhibitor, ezetimibe, is glucuronidated in the intestine, localizes to the intestine, and circulates enterohepatically. (abstr) Atherosclerosis. 151:2000;155.
11. Zhu Y, Statkevich P, Kosoglou T, Maxwell SE, Calzetta A, Patrick J, Cayen MN, Batra V. The effect of gender on the pharmacokinetics of SCH 58235, a cholesterol absorption inhibitor (abstr). AAPS Pharmaceutical Science 1999 AAPS Annual Meeting Supplement;1999:1:S-24. Available at: http://www.aapspharmaceutica.com/scientificjournals/pharmsci/am_abstracts/ 1999/1623.htm.
12. Ezetimibe Study Group, Bays H.E., Moore P.B., Drehobl M.A., Rosenblatt S., Toth P.D., Dujovne C.A., Knopp R.H., Lipka L.J., LeBeaut A.P., Yang B., et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: Pooled analysis of two phase II studies . Clin Ther. 23:2001;1209-1230.
13. Zhu Y., Statkevich P., Kosoglou T., Zambas D., Patrick J., Cayen M.N., Batra V. Effect of ezetimibe (SCH 58235) on the activity of drug metabolizing enzymes in vivo. (abstr) Clin Pharmacol Ther. 67:2000;152.
14. Kosoglou T, Statkevich P, Bauer KS, Cutler DL, Maxwell SE, Yang B, Soni P, Batra VK. Ezetimibe does not affect the pharmacokinetics and pharmacodynamics of digoxin (abstr). AAPS Annual Meeting, Denver, CO, October 2001. Available at: www.aapspharmaceutica.com/search/abstract_view.asp?id=290.
15. Statkevich P., Reyderman L., Kosoglou T., Woloj M., Maxwell S.E., Cutler D.L., Batra V., Kleinermans D. Ezetimibe does not affect the pharmacokinetics and pharmacodynamics of glipizide. (abstr) Clin Pharmacol Ther. 69:2001;P67.
16. Keung A.C.F., Kosoglou T., Statkevich P., Anderson L., Boutros T., Cutler D.L., Batra V., Sellers E.M. Ezetimibe does not affect the pharmacokinetics of oral contraceptives. (abstr) Clin Pharmacol Ther. 69:2001;P55.
17. Bauer K.S., Kosoglou T., Statkevich P., Calzetta A., Maxwell S.E., Patrick J.E., Batra V. Ezetimibe does not affect the pharmacokinetics or pharmacodynamics of warfarin. (abstr) Clin Pharmacol Ther. 69:2001;P5.
18. Stein E. Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor. Eur Heart J. 3:(suppl E):2001;E11-E16.
19. Knopp R.H., Gitter H., Truitt T., Lipka L.J., LeBeaut A.P., Suresh R., Veltri E.P., Ezetimibe Study Group . Ezetimibe reduces low-density lipoprotein cholesterol: Results of a Phase III randomized, double-blind, placebo-controlled trial . (abstr) Atherosclerosis. 2:(suppl):2001;38.
20. Davidson M.H., Dillon M.A., Gordon B., Jones P., Samuels J., Weiss S., Isaacsohn J., Toth P., Burke S.K. Colesevelam hydrochloride (Cholestagel): A new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects . Arch Intern Med. 159:1999;1893-1900.
21. Lipid Research Clinics Program . The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 251:1984;365-374.
22. Knopp RH et al. Ezetimibe reduces low-density lipoprotein cholesterol: Results of a phase III, randomized, double-blind placebo-controlled trial (abstr). Atherosclerosis 2001;2(suppl):38.